Differential TIM-3 glycosylation enables specific dual targeting CAR-T therapy in acute myeloid leukemia
Marta Biondi, Antonio Galeone, Corinne Arsuffi, Bruna My, Erica Grassenis, Camilla Firpo, Maria Caterina Rotiroti, Alice Pievani, Antonio Maria Alviano, Beatrice Cerina, Giuseppe Gigli, Andrea Lia, Andrea Biondi, Sarah Tettamanti, Marta Serafini
This study develops a dual CAR-T therapy targeting CD33 and TIM-3 in AML, showing improved specificity and efficacy through glycosylation-modulated TIM-3 recognition.
bioRxiv · Apr 24, 2026 · PreprintImmunology